Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.1K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.1K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

95
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
95
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Prostate-specific Membrane Antigen Expression In Patients With Primary Prostate Cancer: Diagnostic And Prognostic Value In Positron Emission Tomography-prostate-specific Membrane Antigen

Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen

Omar Tayara1, Sławomir Poletajew1, Wojciech Malewski1

  • 1Second Department of Urology, Centre of Postgraduate Medical Education, 02-511 Warsaw, Poland.

Current Oncology (Toronto, Ont.)
|August 28, 2024

Related Experiment Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.8K

View abstract on PubMed

Summary
This summary is machine-generated.

Prostate-specific membrane antigen (PSMA) PET imaging significantly improves prostate cancer diagnosis and staging. This advanced technique offers superior accuracy compared to traditional methods, enhancing patient management.

Area of Science:

  • Oncology
  • Radiology
  • Biomarker Discovery

Background:

  • Prostate cancer management requires precise diagnostic and prognostic tools.
  • Prostate-specific membrane antigen (PSMA) is a key biomarker overexpressed in prostate cancer.
  • PSMA's role in PET imaging has transformed prostate cancer diagnostics.

Purpose of the Study:

  • To analyze the impact of PET-PSMA imaging on prostate cancer management.
  • To review advancements in PET-PSMA technologies and methodologies.
  • To discuss current challenges and future research directions in PET-PSMA imaging.

Main Methods:

  • Review of recent studies and literature on PET-PSMA imaging.
  • Analysis of diagnostic accuracy and clinical utility across different prostate cancer stages.
Keywords:
18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPy)Carbon-11 Choline (C-11 Choline)Food and Drug Administration (FDA)

Related Experiment Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.8K
  • Comparative effectiveness evaluation against conventional imaging modalities.

    • Main Results:

    • PET-PSMA imaging demonstrates superior diagnostic accuracy and clinical utility in staging prostate cancer.
    • Advancements in radiotracers and imaging protocols enhance sensitivity.
    • PET-PSMA shows comparative effectiveness over conventional imaging.

    Conclusions:

    • PET-PSMA imaging is revolutionizing prostate cancer management.
    • The technology offers significant improvements in diagnosis and staging.
    • Further research is needed to fully integrate and optimize its role in clinical practice.
    Gleason score (GS)
    computed tomography (CT)
    magnetic resonance imaging (MRI)
    positron emission tomography (PET)
    prostate-specific antigen (PSA)
    prostate-specific membrane antigen (PSMA)
    radiomic features (RF)
    seminal vesicle invasion (SVI)